Authors: Gaynor, ER Unger, JM Miller, TP Grogan, TM White, LA Mills, GM Balcerzak, SP Varterasian, M LeBlanc, M Fisher, RI

Citation: Er. Gaynor et al., Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study, J CL ONCOL, 19(3), 2001, pp. 750-755

Authors: Press, OW LeBlanc, M Lichter, AS Grogan, TM Unger, JM Wasserman, TH Gaynor, ER Peterson, BA Miller, TP Fisher, RI

Citation: Ow. Press et al., Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease, J CL ONCOL, 19(22), 2001, pp. 4238-4244

Authors: Fisher, RI Dana, BW LeBlanc, M Kjeldsberg, C Forman, JD Unger, JM Balcerzak, SP Gaynor, ER Roy, V Miller, T

Citation: Ri. Fisher et al., Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809, J CL ONCOL, 18(10), 2000, pp. 2010-2016

Authors: Clark, JI Gaynor, ER Martone, B Budds, SC Manjunath, R Flanigan, RC Waters, WB Sosman, JA

Citation: Ji. Clark et al., Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma, CLIN CANC R, 5(9), 1999, pp. 2374-2380